(Albany, USA) The Nedosiran market forecast report provides analysis of Nedosiran market analysis and forecasts upto 2032 in the major markets. The comprehensive report provides analysis of Nedosiran market potential and Nedosiran market share analysis in primary hyperoxaluria across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2019 to 2032. It helps you to understand the Nedosiran mechanism of action, route of administration, dosage and development activities.
Download Sample Report to know the Nedosiran Market Share: Nedosiran Market Forecast
It presents a thorough description of Nedosiran’s characteristics and its use specifically for primary hyperoxaluria, offering valuable insights into its market potential. The report provides rich insights with respect to the competition in the market as other emerging products that are in the advanced stage of pipeline development for primary hyperoxaluria are expected to give tough market competition to Nedosiran. It is predicted that the launch of late-stage emerging therapies in the near future will significantly impact the primary hyperoxaluria market.
Nedosiran Drug Summary:
Nedosiran, developed by Dicerna Pharmaceuticals (previously known as DCR-PHXC), is an advanced therapy utilizing GalXC RNAi technology to address the treatment of patients with Primary Hyperoxaluria (PH). This therapy targets the lactate dehydrogenase (LDH) enzyme, which plays a role in the excessive production of oxalate. The liver-specific LDH enzyme inhibition is achieved through the incorporation of GalNAc targeting ligands in nedosiran, binding to the asialoglycoprotein receptors (ASGPR) on hepatic cell surfaces. Nedosiran is an RNAi therapy currently in development for all three known types of PH, and its effectiveness is being evaluated through the PHYOX clinical program.
Dicerna has formulated nedosiran as a once-monthly fixed-dose injection, aiming to prevent sudden spikes in oxalate levels that could occur with less frequent administration or missed doses, potentially leading to kidney stone formation and renal failure. To enhance patient convenience, prefilled syringes are being developed to facilitate self-administration by most PH patients, eliminating the need for healthcare provider involvement in dosing. Dicerna is conducting various clinical trials to study and evaluate nedosiran.
In the clinical trial, nedosiran demonstrated safety and tolerability consistent with previous studies in the PHYOX clinical development program. Although there was a trend in reducing urinary oxalate (Uox) levels among patients receiving nedosiran, these reductions did not meet the specified secondary efficacy endpoint criteria.
Despite Dicerna’s shift in focus towards PH1, the company plans to further analyze the PH3 data due to the significant unmet need in that subtype, while also exploring opportunities for licensing nedosiran. The ongoing study(s) are expected to provide supportive data for the submission of the Nedosiran New Drug Application (NDA).
Stay ahead in competition by leveraging insights on Nedosiran market Report: Download Nedosiran Drug Market
Why Nedosiran Market Report?
- Leading Nedosiran for primary hyperoxaluria forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Nedosiran
- Thorough Nedosiran market forecast will help understand how drug is competing with other emerging Nedosiran
- Get analysis of the Nedosiran clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
- The report also provides future market assessments for Nedosiran market forecast analysis for primary hyperoxaluria in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts’ views, detailed overview of market competitors, and short analysis of other emerging therapies in primary hyperoxaluria.
Request for Sample Page @ https://www.delveinsight.com/sample-request/nedosiran-emerging-drug-insight-and-market-forecast
Table of Contents:
1. Report Introduction
2. Nedosiran Overview in Primary Hyperoxaluria
3. Nedosiran Competitive Landscape (Marketed Nedosiran Therapies)
4. Nedosiran Competitive Landscape (Late-stage Emerging Nedosiran Therapies)
5. Nedosiran Market Assessment
5.1. Nedosiran Market Outlook in Primary Hyperoxaluria
5.2. 7MM Nedosiran Market Analysis
5.2.1. Nedosiran Market size in the 7MM for primary hyperoxaluria
5.3. Country-wise Market Analysis
5.3.1. Nedosiran Market size in the United States for primary hyperoxaluria
5.3.2. Nedosiran Market size in Germany for primary hyperoxaluria
5.3.3. Nedosiran Market size in France for primary hyperoxaluria
5.3.4. Nedosiran Market size in Italy for primary hyperoxaluria
5.3.5. Nedosiran Market size in Spain for primary hyperoxaluria
5.3.6. Nedosiran Market size in the United Kingdom for primary hyperoxaluria
5.3.7. Nedosiran Market size in Japan for primary hyperoxaluria
6. Nedosiran SWOT Analysis
7. Analysts’ Views
8. Appendix
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
12. Report Purchase Options
Related reports:
Primary hyperoxaluria Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key primary hyperoxaluria companies, including Dicerna Pharmaceuticals, Inc., Allena Pharmaceutics, Biocodex, and others.
Primary Hyperoxaluria Pipeline
Primary hyperoxaluria Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key primary hyperoxaluria companies, including Dicerna Pharmaceuticals, Inc., Allena Pharmaceutics, Biocodex, and others.
Consulting Services
DelveInsight’s Healthcare Consulting Services offer a comprehensive and customized approach to address the diverse needs of clients in the healthcare sector. These services are specifically designed to tackle the most critical challenges faced by clients while also identifying and capitalizing on emerging opportunities.
By leveraging DelveInsight’s deep industry knowledge, extensive market research capabilities, and advanced data analytics, the healthcare consulting services provide clients with practical and data-driven solutions. The consultants collaborate closely with clients to gain a thorough understanding of their unique requirements and obstacles, enabling them to develop tailored strategies and solutions. DelveInsight’s consulting expertise encompasses various aspects of the healthcare industry, including market access, commercial strategy, product development, and regulatory affairs.
Get in touch today to navigate the complexities of the life sciences industry and successfully achieve your business goals. – https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/3d-cardiac-mapping-system-market